HR 1352 · 118th Congress 2023โ€“2025, ended

Increasing Access to Biosimilars Act of 2023

Latest action · Dec 17, 2024 Referred to the Subcommittee on Health.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedMar 3, 2023
  2. Passed HouseNot reached
  3. Passed SenateNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Increasing Access to Biosimilars Act of 2023

This bill requires the Centers for Medicare & Medicaid Services to establish a demonstration project to evaluate the benefits of providing additional payments to providers of biosimilars under Medicare. Specifically, under the demonstration project, participating providers receive an additional payment based on the difference between the costs to the provider of furnishing the biosimilar and the cost if the provider had furnished the underlying reference biological product instead.

Cosponsors

Members who signed on, in the order they did.

No cosponsors are on file for this measure.

Committees 2

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred Mar 3, 2023Markup Dec 5, 2023Markup Dec 6, 2023
Health Subcommittee
Referred Mar 10, 2023Markup Nov 15, 2023Reported Nov 15, 2023
HouseWays and Means Committee
Referred Mar 3, 2023
Health Subcommittee
Referred Dec 17, 2024

Actions 9

Everything that happened, newest first.

  1. Dec 17, 2024Referred to the Subcommittee on Health.
  2. Dec 6, 2023Committee Consideration and Mark-up Session Held
  3. Dec 6, 2023Ordered to be Reported (Amended) by the Yeas and Nays: 44 - 0.
  4. Dec 5, 2023Committee Consideration and Mark-up Session Held
  5. Nov 15, 2023Subcommittee Consideration and Mark-up Session Held

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Congressional Budget Office cost estimate

  1. Sep 16, 2024H.R. 1352, Increasing Access to Biosimilars Act of 2023As ordered reported by the House Committee on Energy and Commerce on December 6, 2023

Constitutional authority

Congress has the power to enact this legislation pursuant to the following: Article I, Section 8, clause 1 The single subject of this legislation is: Medicare

The sponsor’s statement, as printed in the Congressional Record, vol. 169, no. 41, March 3, 2023, page H1114.

Related bills 1

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
S 3934Increasing Access to Biosimilars Act of 2023Related billMar 14, 2024

Titles 2

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To require the Secretary of Health and Human Services to establish a demonstration project to increase access to biosimilar biological products under the Medicare program.
Short Title(s) as Introduced
Increasing Access to Biosimilars Act of 2023

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Mar 3, 2023Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.